CytRx Corporation Announces Pricing of Public Offering of 8 Million Shares of Common Stock

Published: Oct 18, 2012

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, announced today the pricing of its previously announced underwritten public offering. CytRx is offering 8,000,000 shares of common stock at a public offering price of $2.50 per share for gross proceeds of $20 million, prior to deducting the underwriting discount and estimated offering expenses payable by CytRx.

Back to news